DK3262066T4 - Genterapi - Google Patents

Genterapi Download PDF

Info

Publication number: DK3262066T4
Authority: DK; Denmark
Prior art keywords: gene therapy; therapy; gene
Prior art date: 2015-10-28

Application number

DK16788764.5T

Other languages

English (en)

Other versions

DK3262066T3 (da

Inventor

Christian Groendahl

Tim Funnell

Chris Hollowood

Original Assignee

Syncona Ip Holdco Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-10-28

Filing date

2016-10-27

Publication date

2023-08-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55130363&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3262066(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-10-27 Application filed by Syncona Ip Holdco Ltd filed Critical Syncona Ip Holdco Ltd

2018-05-22 Application granted granted Critical

2018-05-22 Publication of DK3262066T3 publication Critical patent/DK3262066T3/da

2023-08-21 Publication of DK3262066T4 publication Critical patent/DK3262066T4/da

Links

238000001415 gene therapy Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

DK16788764.5T 2015-10-28 2016-10-27 Genterapi DK3262066T4 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1519086.1A GB201519086D0 (en)	2015-10-28	2015-10-28	Gene Therapy
PCT/GB2016/053343 WO2017072515A1 (en)	2015-10-28	2016-10-27	Gene therapy

Publications (2)

Publication Number	Publication Date
DK3262066T3 DK3262066T3 (da)	2018-05-22
DK3262066T4 true DK3262066T4 (da)	2023-08-21

Family

ID=55130363

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK16788764.5T DK3262066T4 (da)	2015-10-28	2016-10-27	Genterapi
DK17210269.1T DK3360890T3 (da)	2015-10-28	2016-10-27	Genterapi

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK17210269.1T DK3360890T3 (da)	2015-10-28	2016-10-27	Genterapi

Country Status (20)

Country	Link
US (2)	US20190255193A1 (da)
EP (3)	EP3786176A1 (da)
JP (2)	JP7126944B2 (da)
KR (1)	KR20180066247A (da)
CN (4)	CN116370655A (da)
AU (2)	AU2016344523B2 (da)
BR (1)	BR112018008731A8 (da)
CA (1)	CA3002125A1 (da)
DK (2)	DK3262066T4 (da)
ES (2)	ES2828050T3 (da)
GB (1)	GB201519086D0 (da)
HK (1)	HK1248723B (da)
IL (3)	IL304084A (da)
MX (1)	MX366343B (da)
NO (1)	NO3262066T3 (da)
PL (2)	PL3262066T5 (da)
RU (1)	RU2740038C2 (da)
SG (1)	SG11201802934WA (da)
WO (1)	WO2017072515A1 (da)
ZA (1)	ZA201802462B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20180055872A (ko)	2015-09-24	2018-05-25	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	보체 매개 질환 치료용 조성물 및 방법
AU2017248731A1 (en)	2016-04-15	2018-10-18	The Trustees Of The University Of Pennsylvania	Compositions for treatment of wet age-related macular degeneration
TWI820034B (zh) *	2017-07-31	2023-11-01	香港商映像生物有限公司	眼部疾病之細胞模式及用於眼部疾病的療法
AU2018351491A1 (en) *	2017-10-20	2020-05-07	Gemini Therapeutics Inc.	Compositions and methods for treating age-related macular degeneration
CA3115782A1 (en) *	2018-10-10	2020-04-16	Wisconsin Alumni Research Foundation	Kir 7.1 gene therapy vectors and methods of using the same
US20210371480A1 (en) *	2018-10-23	2021-12-02	Gemini Therapeutics Inc.	Compositions and methods for treating age-related macular degeneration and other diseases
GB201821082D0 (en) *	2018-12-21	2019-02-06	Gyroscope Therapeutics Ltd	Combination of complement factors i and h, and vector encoding thereof
GB201821089D0 (en) *	2018-12-21	2019-02-06	Gyroscope Therapeutics Ltd	Codon-optimised complement factor I
KR20220004987A (ko) *	2019-04-03	2022-01-12	리젠엑스바이오 인크.	눈 병리에 대한 유전자 요법
GB202009741D0 (en)	2020-06-25	2020-08-12	Freeline Therapeutics Ltd	Polynucleotide
CA3191777A1 (en) *	2020-09-09	2022-03-17	Homology Medicines, Inc.	Vectorized antibodies and uses thereof
US20230390296A1 (en)	2020-10-30	2023-12-07	Keio University	Novel treatment and prevention of sarcopenia-related diseases
GB202018320D0 (en) *	2020-11-20	2021-01-06	Univ Newcastle	Methods of producing recombinant complement proteins
WO2023079297A1 (en)	2021-11-04	2023-05-11	Freeline Therapeutics Limited	Mutant complement factor i variants with increased activity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9803351D0 (en)	1998-02-17	1998-04-15	Oxford Biomedica Ltd	Anti-viral vectors
US6759237B1 (en)	1998-11-05	2004-07-06	The Trustees Of The University Of Pennsylvania	Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
GB0009760D0 (en)	2000-04-19	2000-06-07	Oxford Biomedica Ltd	Method
CN100475846C (zh) *	2003-06-10	2009-04-08	Ns基因公司	增加的神经胚素分泌
CA2597411C (en) *	2005-02-14	2014-08-12	University Of Iowa Research Foundation	Use of complement factor h polymorphisms in treatment and diagnosis of age-related macular degeneration
WO2007047995A2 (en) *	2005-10-21	2007-04-26	Catalyst Biosciences, Inc.	Modified proteases that inhibit complement activation
ES2523640T3 (es) *	2006-06-21	2014-11-28	Musc Foundation For Research Development	Direccionamiento del factor H del complemento para el tratamiento de enfermedades
CA2678774A1 (en) *	2007-03-01	2008-09-04	Advanced Vision Therapies, Inc.	Treatment of diseases characterized by inflammation
CN101657097A (zh) *	2007-03-01	2010-02-24	先进视觉疗法公司	以炎症为特征的疾病的治疗
LT2191001T (lt)	2007-04-09	2016-10-10	University Of Florida Research Foundation, Inc.	Raav vektoriaus kompozicijos, turinčios tirozin-modifikuotų kapsidės baltymų ir jų panaudojimo būdai
GB0816702D0 (en) *	2008-09-12	2008-10-22	Trinity College Dublin	Complement proteins
GB0904427D0 (en) *	2009-03-13	2009-04-29	Lachmann Peter	Treatment of diseases related to hyperactivity of the complement system
TWI702955B (zh) *	2012-05-15	2020-09-01	澳大利亞商艾佛蘭屈澳洲私營有限公司	使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
AU2014209350B8 (en) *	2013-01-23	2019-04-18	Department Of Veterans Affairs (Us)	Targeting constructs based on natural antibodies and uses thereof
US20140234275A1 (en) *	2013-02-15	2014-08-21	Jason Williams	Method for treating als via the increased production of factor h
MX2015014568A (es) *	2013-04-17	2016-12-02	Genzyme Corp	Composiciones y metodos para tratar y prevenir la degeneracion macular.
ES2716615T3 (es) *	2013-06-28	2019-06-13	Inst Nat Sante Rech Med	Métodos para expresar un polinucleótido de interés en la retina de un sujeto
GB201403684D0 (en) *	2014-03-03	2014-04-16	King S College London	Vector
GB201608046D0 (en) *	2016-05-09	2016-06-22	Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The	Treatment of complement-mediated disorders

2015
- 2015-10-28 GB GBGB1519086.1A patent/GB201519086D0/en not_active Ceased
2016
- 2016-10-27 CN CN202310132380.3A patent/CN116370655A/zh active Pending
- 2016-10-27 NO NO16788764A patent/NO3262066T3/no unknown
- 2016-10-27 DK DK16788764.5T patent/DK3262066T4/da active
- 2016-10-27 KR KR1020187015024A patent/KR20180066247A/ko not_active Application Discontinuation
- 2016-10-27 PL PL16788764.5T patent/PL3262066T5/pl unknown
- 2016-10-27 ES ES17210269T patent/ES2828050T3/es active Active
- 2016-10-27 CN CN202310134734.8A patent/CN116271104A/zh active Pending
- 2016-10-27 ES ES16788764T patent/ES2666204T5/es active Active
- 2016-10-27 EP EP20187535.8A patent/EP3786176A1/en active Pending
- 2016-10-27 CN CN202311083674.8A patent/CN117343960A/zh active Pending
- 2016-10-27 CN CN201680073421.4A patent/CN108431030B/zh active Active
- 2016-10-27 RU RU2018118954A patent/RU2740038C2/ru active
- 2016-10-27 US US15/771,849 patent/US20190255193A1/en active Pending
- 2016-10-27 EP EP16788764.5A patent/EP3262066B2/en active Active
- 2016-10-27 CA CA3002125A patent/CA3002125A1/en active Pending
- 2016-10-27 SG SG11201802934WA patent/SG11201802934WA/en unknown
- 2016-10-27 WO PCT/GB2016/053343 patent/WO2017072515A1/en active Application Filing
- 2016-10-27 PL PL17210269T patent/PL3360890T3/pl unknown
- 2016-10-27 AU AU2016344523A patent/AU2016344523B2/en active Active
- 2016-10-27 DK DK17210269.1T patent/DK3360890T3/da active
- 2016-10-27 MX MX2018005145A patent/MX366343B/es active IP Right Grant
- 2016-10-27 JP JP2018541571A patent/JP7126944B2/ja active Active
- 2016-10-27 BR BR112018008731A patent/BR112018008731A8/pt active Search and Examination
- 2016-10-27 EP EP17210269.1A patent/EP3360890B1/en active Active
- 2016-10-27 IL IL304084A patent/IL304084A/en unknown
- 2016-10-27 IL IL284577A patent/IL284577B2/en unknown
2018
- 2018-04-13 ZA ZA2018/02462A patent/ZA201802462B/en unknown
- 2018-04-18 IL IL258806A patent/IL258806B/en unknown
- 2018-06-28 HK HK18108313.3A patent/HK1248723B/zh active IP Right Maintenance
2022
- 2022-05-30 AU AU2022203675A patent/AU2022203675A1/en active Pending
- 2022-06-28 JP JP2022103103A patent/JP2022141670A/ja active Pending
- 2022-12-16 US US18/067,283 patent/US20230277689A1/en active Pending

Also Published As

Publication number	Publication date
IL304084A (en)	2023-08-01
CN117343960A (zh)	2024-01-05
US20230277689A1 (en)	2023-09-07
DK3360890T3 (da)	2020-11-02
BR112018008731A2 (pt)	2018-11-06
RU2740038C2 (ru)	2020-12-30
IL258806A (en)	2018-06-28
PL3360890T3 (pl)	2020-12-28
JP7126944B2 (ja)	2022-08-29
EP3786176A1 (en)	2021-03-03
SG11201802934WA (en)	2018-05-30
PL3262066T3 (pl)	2018-07-31
IL258806B (en)	2021-07-29
PL3262066T5 (pl)	2023-10-30
EP3360890A1 (en)	2018-08-15
MX366343B (es)	2019-07-05
CN108431030B (zh)	2023-10-20
AU2016344523A1 (en)	2018-06-14
DK3262066T3 (da)	2018-05-22
RU2018118954A (ru)	2019-12-02
IL284577B2 (en)	2023-12-01
RU2018118954A3 (da)	2020-03-13
BR112018008731A8 (pt)	2020-03-31
CN108431030A (zh)	2018-08-21
ZA201802462B (en)	2021-01-27
IL284577A (en)	2021-08-31
GB201519086D0 (en)	2015-12-09
AU2022203675A1 (en)	2022-06-16
KR20180066247A (ko)	2018-06-18
ES2828050T3 (es)	2021-05-25
EP3262066A1 (en)	2018-01-03
EP3262066B1 (en)	2018-02-07
ES2666204T5 (es)	2023-11-03
JP2022141670A (ja)	2022-09-29
EP3360890B1 (en)	2020-10-07
MX2018005145A (es)	2018-08-09
US20190255193A1 (en)	2019-08-22
NO3262066T3 (da)	2018-07-07
CA3002125A1 (en)	2017-05-04
EP3262066B2 (en)	2023-06-07
IL284577B1 (en)	2023-08-01
ES2666204T3 (es)	2018-05-03
CN116271104A (zh)	2023-06-23
WO2017072515A1 (en)	2017-05-04
AU2016344523B2 (en)	2022-03-17
HK1248723B (zh)	2019-11-22
JP2018537122A (ja)	2018-12-20
CN116370655A (zh)	2023-07-04

Publication	Publication Date	Title
IL284577A (en)	2021-08-31	Garden healing
DK3283625T3 (da)	2020-03-02	Nukleasemedieret genomeditering
DK3331869T3 (da)	2021-02-15	Muscarinagonister
DK3305788T3 (da)	2020-09-28	Janus-kinase-hæmmer
DK3277719T3 (da)	2022-05-02	Polypeptider
DK3331528T3 (da)	2021-10-25	Muskarinagonister
DK3368678T3 (da)	2021-09-13	Genetisk konstrukt
MA39483A (fr)	2015-09-24	Agents thérapeutiques cibles
DK3310450T3 (da)	2019-08-05	Olie-vand-separator
BR112018005409A2 (pt)	2018-10-09	terapêutica de glicodirecionamento.
DK3331529T3 (da)	2021-10-18	Muskarinagonister
DK3270930T3 (da)	2021-10-04	Præeklampsi
DK3393478T3 (da)	2020-03-23	Kombinationsterapi
DK3292136T3 (da)	2021-03-22	Penicillin-g-acylaser
KR20180084747A (ko)	2018-07-25	Galgt2 유전자 치료 방법 및 물질
DE112015006486A5 (de)	2018-01-04	Inkubationsrinne
DK3318308T3 (da)	2021-12-20	Badmintonketsjer
DK3274482T3 (da)	2020-01-06	Stenborsknop
FR3045729B1 (fr)	2018-10-05	Biomotors gdi
DE112016005599A5 (de)	2018-10-25	Strahlungsgrill
DK3277813T3 (da)	2020-12-21	Hidtil ukendt terapi
DE112015005905A5 (de)	2017-11-02	Gurtschlossbringer
DE102015206660A8 (de)	2016-12-08	Plattenaufteilanlage
DK3329004T3 (da)	2020-04-20	Terapeutiske oligonukleotider
DK3261679T3 (da)	2023-06-26	Genterapi til synsforbedring